Foundation News

Embargoed until 9:00 a.m. ET October 8, 2024

Contact: Rachel Peifer [email protected]

To read the latest press release featuring the Crohn's & Colitis Foundation from the Boca Chamber of Commerce click here!

he Crohn’s & Colitis Foundation has joined forces with life science company Evotec SE, to help advance drug discovery for two innovative drug targets stemming from cutting-edge academic research for inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis.

Seattle, 11/30/2023 — The Northwest Chapter of the Crohn's and Colitis Foundation is proud to recognizeCrohn’s & Colitis Awareness Week from December 1 to 7.

The Crohn’s & Colitis Foundation, the nation’s leading nonprofit organization focused on research and patient support for inflammatory bowel disease (IBD), is joining forces with the Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) to increase awareness of opportunities for accessing some reduced-price essential IBD medications.

Alan Moss, MD, a renowned clinician-scientist, begins his tenure today as the Chief Scientific Officer at the Crohn’s & Colitis Foundation. His prior roles include serving as the Director of the Crohn’s & Colitis Program at Boston Medical Center (BMC) and Professor of Medicine at Boston University (BU). In his clinical practice, Dr. Moss has cared for IBD patients from underserved, immigrant, and unhoused populations.

CHICAGO, Aug.